Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 06/04/26
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/26
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire • 05/07/26
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet SyndromeSeeking Alpha • 05/01/26
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesBusiness Wire • 04/30/26
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/08/26
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeBusiness Wire • 03/04/26
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness Wire • 02/24/26
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)Business Wire • 02/11/26
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business Wire • 02/04/26
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MAPRNewsWire • 01/27/26
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet SyndromeBusiness Wire • 01/11/26
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/26
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%Investors Business Daily • 12/16/25
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?The Motley Fool • 12/11/25